Health status assessment of the elderly.

abstract：OBJECTIVE:To determine whether the use of risperidone in a US managed-care environment is associated with a reduction in the use of mental healthcare services. METHODS:Mental health service use and costs for patients with psychoses treated with risperidone versus those treated with conventional antipsychotic agents we...

journal_title：PharmacoEconomics

authors： Gianfrancesco F,Durkin MB,Mahmoud R,Wang RH

更新日期：2002-01-01 00:00:00

abstract：:A survey of the prescribing of psychotropic drugs was carried out at the Psychiatric Hospital of Bahrain. This retrospective study on 60 inpatients of the Long Stay Ward revealed a man:woman ratio of 2.7. 91% of the men and 88% of the women were over 40 years old. 44 of the 60 patients had a diagnosis of schizophre...

journal_title：PharmacoEconomics

authors： El Hefny F,Al Haddad MK,Mathur V

更新日期：1992-03-01 00:00:00

abstract：INTRODUCTION AND OBJECTIVE:The National Cholesterol Education Program recommends regular physician follow-up and lipid testing to promote adherence with lipid-lowering medications. The objective of this study was to determine whether lipid tests and physician visits after treatment initiation are indeed associated with...

journal_title：PharmacoEconomics

authors： Benner JS,Tierce JC,Ballantyne CM,Prasad C,Bullano MF,Willey VJ,Erbey J,Sugano DS

更新日期：2004-01-01 00:00:00

abstract：:Published estimates for the treatment costs of breast cancer vary widely in methodology, perspective, patient populations and time horizon. We systematically summarized and analysed the published literature on per-patient costs of breast cancer, and highlight the perspectives, populations studied, time horizons and fu...

journal_title：PharmacoEconomics

authors： Campbell JD,Ramsey SD

更新日期：2009-01-01 00:00:00

abstract：:Pharmacoeconomics identifies, measures, and compares the costs and consequences of pharmaceutical products and services. The cost effectiveness of a pharmacotherapy in a particular indication depends on the molecular configuration of the drug, its safety and efficacy, and local market factors such as the acquisition ...

journal_title：PharmacoEconomics

authors： Milne RJ

更新日期：1994-10-01 00:00:00

abstract：OBJECTIVE:The aim of this review is to provide a summary of the literature on risk-sharing agreements, including conceptual, theoretical and empirical (number of agreements and their achievements) perspectives, and stakeholders'  perceptions. METHODS:We conducted a systematic literature search in MEDLINE from 2000 to ...

journal_title：PharmacoEconomics

authors： Antonanzas F,Juárez-Castelló C,Lorente R,Rodríguez-Ibeas R

更新日期：2019-12-01 00:00:00

abstract：AIM:To determine the economic impact (cost-benefit analysis) of childhood varicella vaccination, with the Oka/Merck varicella zoster virus vaccine live (Varivax) in Italy. METHODS:This analysis is based on an epidemiological model of varicella zoster virus (VZV) dynamics adapted to the Italian situation. Cost data (Eu...

journal_title：PharmacoEconomics

authors： Coudeville L,Brunot A,Giaquinto C,Lucioni C,Dervaux B

更新日期：2004-01-01 00:00:00

abstract：:Decision-analytic models play a key role in informing healthcare resource allocation decisions. However, there are ongoing concerns with the credibility of models. Modelling methods guidance can encourage good practice within model development, but its value is dependent on its ability to address the areas that modell...

journal_title：PharmacoEconomics

authors： Husbands S,Jowett S,Barton P,Coast J

更新日期：2017-06-01 00:00:00

abstract：OBJECTIVE:To examine the relative cost effectiveness of topical calcipotriol and short-contact dithranol in the treatment of mild to moderate plaque psoriasis. DESIGN AND SETTING:This was a modelling study from the perspective of the UK National Health Service as payer. METHODS:The interventions were compared using 2...

journal_title：PharmacoEconomics

authors： Ashcroft DM,Li Wan Po A,Williams HC,Griffiths CE

更新日期：2000-11-01 00:00:00

abstract：BACKGROUND:Probabilistic sensitivity analysis (PSA) in cost-effectiveness analysis involves sampling a large number of realisations of an economic model. For some parameters, we may be uncertain around the true mean values of the variables, but the ordering of the values is known. Typical sampling approaches lack eithe...

journal_title：PharmacoEconomics

authors： Ren S,Minton J,Whyte S,Latimer NR,Stevenson M

更新日期：2018-03-01 00:00:00

abstract：BACKGROUND AND OBJECTIVE:Patient heterogeneity is the part of variability that can be explained by certain patient characteristics (e.g. age, disease stage). Population reimbursement decisions that acknowledge patient heterogeneity could potentially save money and increase population health. To date, however, economic ...

journal_title：PharmacoEconomics

authors： Grutters JP,Sculpher M,Briggs AH,Severens JL,Candel MJ,Stahl JE,De Ruysscher D,Boer A,Ramaekers BL,Joore MA

更新日期：2013-02-01 00:00:00

abstract：:Which costs and benefits to consider in economic evaluations of healthcare interventions remains an area of much controversy. Unrelated medical costs in life-years gained is an important cost category that is normally ignored in economic evaluations, irrespective of the perspective chosen for the analysis. National gu...

journal_title：PharmacoEconomics

authors： Rappange DR,van Baal PH,van Exel NJ,Feenstra TL,Rutten FF,Brouwer WB

更新日期：2008-01-01 00:00:00

abstract：:Fluconazole (FLU) is an alternative to amphotericin B (AMB) for the treatment of candidemia in non-neutropenic patients. This agent has similar clinical efficacy but significantly reduced adverse effects compared with AMB. Using the database from a Canadian randomised multicentre comparative trial of FLU versus AMB in...

journal_title：PharmacoEconomics

authors： Dranitsaris G,Phillips P,Rotstein C,Puodziunas A,Shafran S,Garber G,Smaill F,Salit I,Miller M,Williams K,Conly J,Singer J,Ioannou S

更新日期：1998-05-01 00:00:00

abstract：:A systematic review of dementia cost-of-illness (COI) studies in the US and Canada was conducted to explore the policy-making relevance of these studies. MEDLINE, CINAHL, EconLit, AMED and the Cochrane Library were searched from inception to March 2010 for English-language COI articles. Content analysis was used to ex...

journal_title：PharmacoEconomics

authors： Oremus M,Aguilar SC

更新日期：2011-02-01 00:00:00

abstract：BACKGROUND:Dengue disease poses a great economic burden in Malaysia. METHODS:This study evaluated the cost effectiveness and impact of dengue vaccination in Malaysia from both provider and societal perspectives using a dynamic transmission mathematical model. The model incorporated sensitivity analyses, Malaysia-speci...

journal_title：PharmacoEconomics

authors： Shafie AA,Yeo HY,Coudeville L,Steinberg L,Gill BS,Jahis R,Amar-Singh Hss

更新日期：2017-05-01 00:00:00

abstract：:Rheumatoid arthritis (RA) is a chronic, generally progressive autoimmune disease that causes functional disability, significant pain and joint destruction, and leads to premature mortality. It is estimated to affect between 0.5 and 1.0% of the adult population worldwide, increases in prevalence with age and affects mo...

journal_title：PharmacoEconomics

authors： Kvien TK

更新日期：2004-01-01 00:00:00

abstract：:Currently, the most important issue in US pharmaceutical policy is probably cost containment. Research into pharmaceutical issues should therefore concentrate on this area. Analysis of changing trends in pharmaceutical expenditures, particularly during the early 1990s, would be a useful starting point. Research into t...

journal_title：PharmacoEconomics

authors： Meyer PR

更新日期：1996-01-01 00:00:00

abstract：:Epidural analgesia and intravenous analgesia with opioids are two techniques for providing pain relief for women in labour. Labour pain is comparable to surgical pain in its severity, and epidural analgesia provides better relief from this pain than intravenous analgesia; a meta-analysis quantified this improvement to...

journal_title：PharmacoEconomics

authors： Huang C,Macario A

更新日期：2002-01-01 00:00:00

abstract：OBJECTIVE:The study objective was to evaluate and compare quality-of-life (QOL) parameters between patients with type 2 (non-insulin-dependent) diabetes mellitus who changed therapy from an oral hypoglycaemic agent (OHA) to insulin and those who remained on an OHA. DESIGN:The World Health Organization Quality of Life ...

journal_title：PharmacoEconomics

authors： Pibernik-Okanović M,Szabo S,Metelko Z

更新日期：1998-08-01 00:00:00

abstract：:This tutorial presents practical guidance on transforming various types of information published in journals, or available online from government and other sources, into transition probabilities for use in state-transition models, including cost-effectiveness models. Much, but not all, of the guidance has been previou...

journal_title：PharmacoEconomics

authors： Gidwani R,Russell LB

更新日期：2020-11-01 00:00:00

abstract：:In an attempt to obtain an appropriate estimate of the excess costs of production losses arising from morbidity in patients with diabetes, we compared the number of sick days and permanently disabled individuals in a diabetic population and the corresponding general population. These comparisons show that the rate of ...

journal_title：PharmacoEconomics

authors： Persson U

更新日期：1995-01-01 00:00:00

abstract：BACKGROUND:Recent randomised trials have demonstrated a statistically significant effect of trastuzumab on disease-free survival when used as adjuvant therapy for human epidermal growth factor receptor 2 protein (HER2)-positive resectable early stage breast cancer, with a treatment course lasting either 9 or 52 weeks. ...

journal_title：PharmacoEconomics

authors： Millar JA,Millward MJ

更新日期：2007-01-01 00:00:00

abstract：BACKGROUND:Given the limited availability of healthcare resources and the recent introduction of new anti-osteoporosis drugs, the interest in the cost effectiveness of drugs in postmenopausal osteoporosis remains and even increases. OBJECTIVE:This study aims to identify all recent economic evaluations on drugs for pos...

journal_title：PharmacoEconomics

authors： Hiligsmann M,Evers SM,Ben Sedrine W,Kanis JA,Ramaekers B,Reginster JY,Silverman S,Wyers CE,Boonen A

更新日期：2015-03-01 00:00:00

abstract：:About half of the world's population live in Asia. Mandarin (the official language of China), Hindi and Japanese are among the ten languages spoken by the largest number of primary speakers. The numbers of Tamil and Malay speakers are expected to grow rapidly in the next few decades. Most health-related quality-of-lif...

journal_title：PharmacoEconomics

authors： Cheung YB,Thumboo J

更新日期：2006-01-01 00:00:00

abstract：OBJECTIVE:A cost-effectiveness analysis of oral capecitabine versus intravenous bolus 5-fluorouracil/l-leucovorin (FU/LV) as adjuvant therapy in patients with stage 3 colon cancer was performed from a Japanese healthcare payer perspective. METHODS:Adjuvant therapy comprised 24 weeks of treatment with either oral capec...

journal_title：PharmacoEconomics

authors： Shiroiwa T,Fukuda T,Shimozuma K,Ohashi Y,Tsutani K

更新日期：2009-01-01 00:00:00

abstract：BACKGROUND AND AIM:Buprenorphine offers an alternative to methadone in the treatment of heroin dependence, and has the advantage of allowing alternate-day dosing. This study is the first to examine the cost effectiveness of buprenorphine as maintenance treatment for heroin dependence in a primary care setting using eco...

journal_title：PharmacoEconomics

authors： Harris AH,Gospodarevskaya E,Ritter AJ

更新日期：2005-01-01 00:00:00

abstract：:Patients with schizophrenia suffer numerous relapses and rehospitalizations that are associated with high direct and indirect medical expense. Suboptimal therapeutic efficacy and, in particular, problems with compliance are major factors leading to relapse. Atypical antipsychotic agents offer improved efficacy and a l...

journal_title：PharmacoEconomics

authors： De Graeve D,Smet A,Mehnert A,Caleo S,Miadi-Fargier H,Mosqueda GJ,Lecompte D,Peuskens J

更新日期：2005-01-01 00:00:00

abstract：OBJECTIVE:The objective of this study was to evaluate the cost effectiveness of no prophylaxis, primary prophylaxis (PP), or secondary prophylaxis (SP) with granulocyte colony-stimulating factors (G-CSFs), i.e., pegfilgrastim, lipegfilgrastim, filgrastim (6- and 11-day), or lenograstim (6- and 11-day), to reduce the in...

journal_title：PharmacoEconomics

authors： Fust K,Li X,Maschio M,Villa G,Parthan A,Barron R,Weinstein MC,Somers L,Hoefkens C,Lyman GH

更新日期：2017-04-01 00:00:00

abstract：:Cost-utility analysis (CUA) is a technique that can potentially be used as a guide to allocating healthcare resources so as to obtain the maximum health benefits possible under a given budget constraint. However, it is not clear that current practice captures societal preferences regarding health benefits. In analyses...

journal_title：PharmacoEconomics

authors： Cohen BJ

更新日期：2003-01-01 00:00:00

abstract：:Pharmacoeconomic data may be obtained within the context of randomised clinical trials (RCTs) and from effectiveness studies in the 'real world'. The differences between the 2 types of study design have implications for the types of data that can be obtained and the interpretation of the resulting findings. Because RC...

journal_title：PharmacoEconomics

authors： Revicki DA,Frank L

更新日期：1999-05-01 00:00:00